Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hangzhou Just Biotherapeutics
Hangzhou, Zhejiang, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Before its acquisition and merger into Transcenta, Hangzhou Just Biotherapeutics primarily operated as a biotherapeutics platform and CDMO with an internal early‑stage pipeline (including bionovel and biosimilar biologics) but no independently commercialized products reported.[2][4][13]
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyRecombinant proteinRecombinant fusion proteinAntibody-drug conjugateSmall interfering RNABiologic
- Industry
- Biotech
02
Partnerships
Merck (strategic collaboration/funding as Series A investor)[3][8]ARCH Venture Partners (investor)[3]Lilly Asia Ventures (investor)[3]BOCGI Zheshang Capital (investor)[3]
Beyond the preview
Go deeper on Hangzhou Just Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hangzhou Just Biotherapeutics.